Psoriatic Arthritis FocusRheum

Background/Purpose Psoriasis and psoriatic arthritis (PsA) are closely linked inflammatory conditions that can affect both children and adults. In children, these diseases are associated with traditional cardiovascular disease risk factors and subclinical atherosclerosis. In older adults, systemic inflammation from psoriasis and PsA accelerates atherosclerosis, and these conditions are independent risk factors for severe cardiovascular disease…

A phase 2 clinical trial has demonstrated the effectiveness for multiple doses of subcutaneous sonelokimab for the treatment of adults with active psoriatic arthritis.

The ACR places a high priority on developing relevant, practical guidance for the rheumatology community. A current ACR project on musculoskeletal ultrasound (MSUS) will be discussed in the ACR Convergence 2024 session, Proposed ACR Guidance for Use of Musculoskeletal Ultrasound in Rheumatoid and Psoriatic Arthritis, on Saturday, Nov. 16. In the session, Veena K. Ranganath,…

In patients with psoriatic arthritis (PsA), their sex matters. In the session Sex Differences in Psoriatic Arthritis, Laura Coates, MD, PhD, of the University of Oxford, and Lihi Eder, MD, PhD, of the University of Toronto, will discuss sex-related differences in clinical features, disease course, treatment response and pain perception in patients with PsA. The…

What research on psoriatic arthritis to be presented at ACR Convergence 2024 has the greatest potential for a positive impact on clinical care, treatment options or serve as the basis for future research? That’s the question The Rheumatologist asked David S. Pisetsky, MD, PhD—our founding editor—to consider. With thousands of research abstracts to be presented…

As part of the Review Course on Friday Nov. 15 at ACR Convergence 2024, Ana-Maria Orbai, MD, MHS, associate professor of medicine and director of the Psoriatic Arthritis Program at the Johns Hopkins School of Medicine, will present a session reviewing the management of psoriatic arthritis. Dr. Orbai earned her medical degree from the Iuliu…

Upadacitinib, as a tablet and oral solution, is now FDA approved to treat children age 2 years and older with active polyarticular juvenile idiopathic arthritis or psoriatic arthritis.

Biosimilars have become a therapeutic turning point for many patients who are living with rheumatic illnesses. Psoriatic arthritis (PsA) is a complex, multi-faceted chronic inflammatory musculoskeletal and skin disease where the treatment has changed considerably over the past few years. Psoriatic arthritis has an impact on about 30% of people with psoriasis.1 In 2019, the…

After years of legal disputes between drug makers, adalimumab-atto (Amjevita) biosimilar to adalimumab (Humira) is now available in the U.S. to treat rheumatoid arthritis and other diseases. Adalimumab-atto is the first of several biosimilars to adalimumab expected to become available in the U.S. in 2023.

PHILADELPHIA—Selecting my top 10 picks for abstracts in psoriatic arthritis (PsA) at the ACR Convergence 2022 meeting was not easy because there was a great deal to review and learn from the 139 abstracts submitted to the meeting. I focused first and foremost on advances in therapeutics that encompassed both new and approved therapeutics, novel…